Active Broker’s Choice in Focus: Merrimack Pharmaceuticals (NASDAQ:MACK), Accuray (NASDAQ:ARAY)

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -4.11% to $4.20. Merrimack Pharmaceuticals, Inc. (MACK) reported that, following a recent independent Data and Safety Monitoring Board (DSMB) recommendation and subsequent futility analysis, it has decided to stop the Phase 2 HERMIONE study of MM-302 (HER2 antibody-targeted liposomal doxorubicin) in HER2-positive metastatic breast cancer patients who had previously been treated with trastuzumab (Herceptin), pertuzumab (Perjeta) and ado-trastuzumabemtansine (T-DM1, Kadcyla).

The decision to stop the trial was made following the DSMB’s opinion that continuing would be unlikely to demonstrate benefit over the comparator treatments. Subsequent to this recommendation, a futility assessment was performed that confirmed the DSMB’s opinion. Both the treatment and control arms were found to have shorter than expected median progression free survival. The share price of MACK attracts active investors, as stock price of week volatility recorded 5.84%. The stock is going forward to its 52-week low with -3.45% and lagging behind from its 52-week high price with -53.44%.

Accuray Incorporated (NASDAQ:ARAY) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it remains unchanged to close at $4.75 with the total traded volume of 1.47 Million shares. Accuray Incorporated (ARAY) declared that has signed an contract with Hong Kong Sanatorium & Hospital (HKSH) for the acquisition of three RadixactTM Systems that will provide clinicians and their patients with access to the newest advanced radiation therapy. Of the three Radixact Systems, two will replace existing TomoTherapy Systems and one will be installed in a new bunker.

The contract also includes an upgrade of HKSH’s existing CyberKnife® M6™ System to include the latest features for motion management and treatment efficiency, and was entered into backlog during Accuray’s second fiscal quarter which ends December 31, 2016. The firm has institutional ownership of 95.10%, while insider ownership included 4.00%. Its price to sales ratio ended at 0.97. ARAY attains analyst recommendation of 2.70 with week performance of -3.06%.


About Aaron Smithies

Aaron Smithies has a wide look on current monetary and financial events. He is an editor and a writer. His views; At Streetwise Report, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Interests: Biotech, Finical markets, Dividend stock ideas & income, Energy stocks, Consumer goods stocks

Leave a Reply

Your email address will not be published. Required fields are marked *